DrugDashboards

Brimonidine Tartrate And Timolol Maleate

Brimonidine tartrate and Timolol maleate · BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL · Solution · Ophthalmic · Florida Pharmaceutical Products, LLC

NDC 71921-0188-10 · 1 BOTTLE, DROPPER in 1 CARTON / 10 mL in 1 BOTTLE, DROPPER · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 52% in a year, to $2.46 per mL — and generics that get this cheap tend to get abandoned rather than defended. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$10.00$20.00Jan 2024Sep 2026$2.46
33 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$247.20
Reported to Texas DSHS · 2026 annual filing · Florida Pharmaceutical Products, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$12,862
79 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

28Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 4 active manufacturers+5
  • Class I/II recall on same molecule/form in past 12 months+8
  • price down 47% year over year+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for brimonidine tartrate and timolol maleate (other) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · 2 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA201949
TE code
AB
Approval date
Oct 4, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Brimonidine tartrate and Timolol maleate (Solution)

LabelerStrengthFirst seenLast seen
Caplin Steriles LimitedBRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 3, 2026
Apotex Corp.BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 2, 2026
Florida Pharmaceutical Products, LLCBRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 2, 2026
Leading Pharma, LLCBRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brimonidine Tartrate And Timolol Maleate — NDC 71921-0188-10," retrieved September 3, 2026, https://drugdashboards.com/drug/71921018810.

Free to cite with attribution — see how the data is put together.